← Back to Search
Immunization With The Chlamydia Trachomatis Major Outer Membrane Protein, Using Adjuvants Developed For Human Vaccines, Can Induce Partial Protection In A Mouse Model Against A Genital Challenge.
S. Pal, E. Peterson, R. Rappuoli, G. Ratti, L. M. de la Maza
Published 2006 · Biology, Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
To test several vaccines for Chlamydia trachomatis we vaccinated BALB/c and C3H/HeN female mice with a purified preparation of the native mouse pneumonitis (MoPn) major outer membrane protein (MOMP). The MOMP was formulated with anyone of three different adjuvants MF59, LT-K63 or LT-R72. As a negative control the animals were immunized with ovalbumin. Positive controls were inoculated intranasally (i.n.) with 10(4) inclusion-forming units (IFU) of C. trachomatis MoPn. High levels of Chlamydia-specific antibodies were detected in the serum and vaginal washes of the mice immunized with MOMP. Using a lymphoproliferative assay (LPA) a significant response was obtained in splenocytes from most of the groups of mice vaccinated with MOMP. Two weeks after the last immunization the mice were challenged in the left ovarian bursa with 10(5) IFU of C. trachomatis MoPn and vaginal cultures were collected for a period of 6 weeks. Overall, BALB/c and C3H/HeN mice immunized with MOMP showed a decrease in the severity and length of the infection but the difference with the controls was not statistically significant. Following mating the percentage of mice with bilateral fertility was not significantly different between mice vaccinated with MOMP and their respective ovalbumin-immunized controls. However, the C3H/HeN mice immunized with MOMP using MF59 or LTR72 as adjuvants had significantly more embryos per mouse than the control groups. In conclusion, mice immunized with native MOMP and adjuvants developed for human vaccines showed significant Chlamydia-specific immune response and a limited protection against infection and long-term sequelae.
This paper references
AN UNIDENTIFIED VIRUS WHICH PRODUCES PNEUMONIA AND SYSTEMIC INFECTION IN MICE.
C. Nigg (1942)
New knowledge of chlamydiae and the diseases they cause.
J. T. Grayston (1975)
Human chlamydial infections
J. Schachter (1978)
The potential for vaccine against infection of the genital tract with Chlamydia trachomatis.
Grayston Jt (1978)
Progesterone as a key factor in the development of a mouse model for genital-tract infection with Chlamydia trachomatis
M. Tuffrey (1981)
Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis
H. Caldwell (1981)
Diversity of Chlamydia trachomatis major outer membrane protein genes
R. Stephens (1987)
Oral immunization with chlamydial major outer membrane protein (MOMP).
H. Taylor (1988)
Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity
E. Peterson (1988)
Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein
R. Morrison (1989)
Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.
Washington Ae (1991)
Sequence of the gene encoding the major outer membrane protein of the mouse pneumonitis biovar of Chlamydia trachomatis.
T. Fielder (1991)
Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein.
M. Tuffrey (1992)
Pelvic Inflammatory Disease and Fertility: A Cohort Study of 1,844 Women with Laparoscopically Verified Disease and 657 Control Women with Normal Laparoscopic Results
L. Weström (1992)
Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones.
M. Piccinni (1995)
A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections.
Michael de la Maza (1995)
Progesterone inhibits inducible nitric oxide synthase gene expression and nitric oxide production in murine macrophages
Lance Miller (1996)
Prospects for a vaccine against Chlamydia genital disease I. — Microbiology and pathogenesis
P. Bavoil (1996)
Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi.
C. Luke (1997)
OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
L. Erdile (1997)
Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity
M. Giuliani (1998)
A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.
L. Sigal (1998)
Effects of Estradiol and Progesterone on Susceptibility and Early Immune Responses to Chlamydia trachomatis Infection in the Female Reproductive Tract
C. Kaushic (2000)
The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunisation with human papillomavirus type 6b (HPV-6b) virus-like particles.
C. Greer (2000)
Oral Administration of Influenza Vaccine in Combination with the Adjuvants LT-K63 and LT-R72 Induces Potent Immune Responses Comparable to or Stronger than Traditional Intramuscular Immunization
J. Barackman (2001)
Immunization with the Chlamydia trachomatis Mouse Pneumonitis Major Outer Membrane Protein Can Elicit a Protective Immune Response against a Genital Challenge
Sukumar Pal (2001)
Immunity to Murine Chlamydial Genital Infection
R. Morrison (2002)
Vaccines for Chlamydia trachomatis infections.
L. M. de la Maza (2002)
Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults.
S. Frey (2003)
Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
S. Pal (2003)
Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.
W. Ballou (2003)
DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H/HeN mice.
M. Donati (2003)
Prevalence of chlamydial and gonococcal infections among young adults in the United States.
W. Miller (2004)
Mucosal Vaccination against Serogroup B Meningococci: Induction of Bactericidal Antibodies and Cellular Immunity following Intranasal Immunization with NadA of Neisseria meningitidis and Mutants of Escherichia coli Heat-Labile Enterotoxin
F. Bowe (2004)
This paper is referenced by
A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars
A. Olsen (2021)
Induction of protection in mice against a respiratory challenge by a vaccine formulated with exosomes isolated from Chlamydia muridarum infected cells
S. Pal (2020)
Chlamydia: what is on the outside does matter
Arlieke Gitsels (2020)
Suppression of Chlamydial Pathogenicity by Nonspecific CD8+ T Lymphocytes
Lingxiang Xie (2020)
A primary study on genes with selected mutations by in vitro passage of Chlamydia muridarum strains.
Z. Zhou (2019)
Anti‐chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti‐chlamydia IgG is associated with enhanced risk for incident infection
T. Darville (2019)
Evaluating Potential Vaccine Antigens in both the Chlamydia trachomatis and Chlamydia muridarum Intravaginal Mouse Challenge Models
R. Kaufhold (2019)
Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens
G. Madico (2017)
Update on Chlamydia trachomatis Vaccinology
L. M. de la Maza (2017)
National Institute of Allergy and Infectious Diseases workshop report: "Chlamydia vaccines: The way forward".
G. Zhong (2017)
Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates
S. Vasilevsky (2016)
Molecular characterization of the polymorphic membrane proteins of Chlamydia psittaci
S. V. Lent (2016)
MRI as a Novel In Vivo Approach for Assessing Structural Changes of Chlamydia Pathology in a Mouse Model
C. Hines (2016)
Comparison of subcutaneous versus intranasal immunization of male koalas (Phascolarctos cinereus) for induction of mucosal and systemic immunity against Chlamydia pecorum.
C. Waugh (2015)
Quantitative In Vivo Detection of Chlamydia muridarum Associated Inflammation in a Mouse Model Using Optical Imaging
M. Patel (2015)
Immune Regulation of Chlamydia trachomatis Infections of the Female Genital Tract
L. Hafner (2014)
CTA 1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the genital mucosa
K. Cunningham (2014)
Development status and future prospects for a vaccine against Chlamydia trachomatis infection.
Louise M. Hafner (2014)
Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine
Stacie J. Fairley (2013)
Antigenic specificity of a monovalent versus polyvalent MOMP based Chlamydia pecorum vaccine in koalas (Phascolarctos cinereus).
A. Kollipara (2013)
Intranasal Vaccination with Chlamydia pneumoniae Induces Cross-Species Immunity against Genital Chlamydia muridarum Challenge in Mice
S. Manam (2013)
Recognition and treatment of chlamydial infections from birth to adolescence.
T. Darville (2013)
Chapter 15 – Chlamydia
L. Hafner (2013)
Vaccination of Koalas with a Recombinant Chlamydia pecorum Major Outer Membrane Protein Induces Antibodies of Different Specificity Compared to Those Following a Natural Live Infection
A. Kollipara (2013)
Chlamydia muridarum T Cell Antigens and Adjuvants That Induce Protective Immunity in Mice
Hong B Yu (2012)
Vaccination to protect against infection of the female reproductive tract
W. Huston (2012)
167 – Chlamydia trachomatis
T. Darville (2012)
High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge.
M. Picard (2012)
Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide.
M. Taha (2012)
Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.
A. Slepenkin (2011)
Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines
O. Finco (2011)
Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges
Brandie D Taylor (2011)See more